MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, UTHR made $781,500K in revenue. $274,900K in net income. Net profit margin of 35.18%.

Income Overview

Revenue
$781,500K
Net Income
$274,900K
Net Profit Margin
35.18%
EPS
$5.82
Unit: Thousand (K) dollars
Revenue Breakdown
    • Tyvaso DPI
    • Orenitram
    • Nebulized Tyvaso
    • Others
Revenue Breakdown
    • US
    • Non Us

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenues
781,500 790,200 799,500 798,600
Cost of sales
133,400 103,400 100,900 87,600
Research and development
138,200 139,500 127,500 134,000
Selling, general, and administrative
184,100 190,600 182,600 212,500
Total operating expenses
455,700 433,500 411,000 434,100
Operating income
325,800 356,700 388,500 364,500
Interest income
41,800 43,200 46,400 51,300
Interest expense
3,000 3,100 3,000 7,300
Other expense, net
-46,300 47,200 6,100 -100
Total other (expense) income, net
-7,500 87,300 49,500 43,900
Income before income taxes
318,300 444,000 438,000 408,400
Income tax expense
43,400 79,700 99,300 98,900
Net income
274,900 364,300 338,700 309,500
Basic EPS
6.32 8.394 7.73 6.86
Diluted EPS
5.82 7.686 7.16 6.41
Basic Average Shares
43,500,000 43,400,000 43,800,000 45,100,000
Diluted Average Shares
47,200,000 47,400,000 47,300,000 48,300,000
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
US$112,600K Non Us$14,600K US$108,800K Non Us$17,800K US$49,000K Non Us$4,600K US$5,000K Non Us$300K Tyvaso DPI$330,300K Orenitram$135,600K Nebulized Tyvaso$127,200K Remodulin$126,600K Unituxin$53,600K Product And ServiceOther$5,300K Adcirca$2,900K Total revenues$781,500K (-1.62%↓ Y/Y)Operating income$325,800K (-14.89%↓ Y/Y)Total operatingexpenses$455,700K (10.71%↑ Y/Y)Income before incometaxes$318,300K (-24.84%↓ Y/Y)Total other (expense)income, net-$7,500K (-118.43%↓ Y/Y)Interest income$41,800K (-18.20%↓ Y/Y)Selling, general, andadministrative$184,100K (8.23%↑ Y/Y)Research and development$138,200K (-7.25%↓ Y/Y)Cost of sales$133,400K (44.22%↑ Y/Y)Net income$274,900K (-14.68%↓ Y/Y)Income tax expense$43,400K (-57.16%↓ Y/Y)Other expense, net-$46,300K (-976.74%↓ Y/Y)Interest expense$3,000K (-50.82%↓ Y/Y)

UNITED THERAPEUTICS Corp (UTHR)

UNITED THERAPEUTICS Corp (UTHR)